Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the therapeutic efficacy and safety of venetoclax in combination
with azacitidine and CAG as induction regimen in Patients with Refreactory/Relapse Acute
Myeloid Leukemia.